Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 161
Summary
- Conditions
- Endometrial Cancer
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: double blind placebo controlled studyPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03555422
- Collaborators
- Belgium and Luxembourg Gynaecological Oncology Group
- North-Eastern German Society of Gynaecologic Oncology
- Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies
- Spanish Research Group in Ovarian Cancer
- Central and Eastern European Gynecologic Oncology Group
- Israel Society of Gynecologic Oncology
- The GOG Foundation, Inc.
- Investigators
- Study Director: Michael Kauffman, MD, PhD Karyopharm Therapeutics Inc